TickerFacts.

Company research / IMCR

Immunocore Holdings plc (IMCR)

Build a valuation ↗↓ Download CSV

CIK 0001671927 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Immunocore Holdings plc reported revenue of $400.02M. Revenue grew 29.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $430.77M.

Key ratios (year ended 2025-12-31)

-11.3%
Operating margin
-8.9%
Net margin
-9.3%
Return on year-end equity
29.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$430.77M$400.02M$310.20M$249.43M$174.36M$36.48M
Cost of Revenue$4.74M$5.09M$2.73M$1.04M$1.09M$0
R&D Expense$284.45M$274.87M$222.15M$163.54M$101.92M$100.25M
Operating Income-$22.58M-$45.35M-$70.46M-$59.65M-$51.71M-$174.59M
Depreciation & Amortizationn/a$3.10M$4.20M$4.10M$5.30M$7.60M
EBITDAn/a-$42.25M-$66.26M-$55.55M-$46.41M-$166.99M
Net Income-$18.07M-$35.51M-$51.09M-$55.29M-$52.54M-$180.03M
EPS (Diluted)n/a-$0.71-$1.02-$1.13-$1.15-$4.24
Total Assets$1.12B$1.07B$1.01B$597.00M$526.76Mn/a
Total Liabilities$699.62M$686.24M$648.79M$228.16M$187.86Mn/a
Shareholders' Equity$419.80M$381.03M$360.72M$368.84M$338.90M$233.71M
Cash & Equivalents$484.92M$467.71M$455.73M$442.63M$402.47Mn/a
Operating Cash Flow-$34.96M-$10.71M$26.06M$2.94M-$49.21M-$143.11M
Capital Expenditures$6.20M$4.34M$5.17M$5.42M$2.20M$1.39M
Free Cash Flow-$41.15M-$15.05M$20.89M-$2.48M-$51.41M-$144.49M
Shares Outstanding51.48M50.69M50.06M49.73M48.09Mn/a
Dividends Per Sharen/a$0.00$0.00$0.00$0.00n/a
Weighted Average Diluted Sharesn/a50.35M49.99M48.89M45.71M42.49M
EPS (Basic)n/a-$0.71-$1.02-$1.13-$1.15-$4.24

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView